The Global Bioequivalence Studies Market is expected to reach a value of USD 1451.7 Million by 2032, expanding at 8.2% CAGR between 2022 and 2032. he market for Bioequivalence Studies is a rapidly expanding sector of the pharmaceutical industry. These studies play an important role in determining the comparable quality of a generic drug to its reference product, ensuring patient safety and efficacy.